Auto-injectors Market, By Technology, Usability, Design,
Application, and Distribution Channel - Global Trends,
and Forecast 2018-2026
Auto-injector is a needle based medical device which is used for the administration of a fixed
dose of a particular drug. It can be used for self-administration by the patients or untrained
person, as it is easy to handle. Furthermore, auto-injector is significantly used for various mild
and severe allergic reactions. If allergic reaction are not cured, then it can even lead to life-
threatening condition such as anaphylaxis. Allergy symptoms include trouble in breathing,
wheezing, nausea, stomach pain, vomiting, dizziness, faint, swelling of face, mouth, lips, and
tongue and skin reactions such as itching, hives, and flushing. Moreover, site of administration
depends on the nature of the drug. For instance, insulin shots are always injected in the
abdomen site to make them work fast. However, a long term allergy effect caused by food,
dust, pollen, and many more substances can lead to life-threatening crisis, which is expected to
fuel growth of the auto-injectors market.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/1035
Advancement of auto-injector devices to provide more access to the patients is expected to
drive growth of the market:
In 2017, Kaleo Pharmaceutical announced supplemental new drug application (sNDA) named as
– AUVI-Q (0.1mg), which was granted a priority review by the U.S. Food and Drug
Administration (US FDA). AUVI-Q is the first known epinephrine auto-injector, which is
designed to treat an allergic reactions especially in infants, weighing around 16.6 to 33 pounds.
According to the study by Allergy, Asthma & Clinical Immunology, children’s treated with
anaphylaxis has limit of around 0.15 mg per auto-injector, which should have 12.7mm needle
length and mainly used for patients with high-risk. The high dose of drug use in life-
threatening condition, could strike the bone during the administration of epinephrine. Moreover,
National Institute of Health (NIH) guidelines recommended AUVI-Q 0.1 mg for peanut allergy,
as it contains no epinephrine auto-injector (EAI). Thus, AUVI-Q 0.1mg is mainly designed to
minimize complications during treatment of pediatric patients.
Furthermore, Kaleo